Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for postprandial hyperinsulinemic hypoglycaemia after bariatric surgery
2020-006127-34Phase 2Completed
- Sponsor
- Verein zur Förderung der Wissenschaft und Forschung an der 1. Med. Abteilung der Klinik Ottakring
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in Postprandial hyperinsulinemic hypoglycemia (PHH) (2 arms), sponsored by Verein zur Förderung der Wissenschaft und Forschung an der 1. Med. Abteilung der Klinik Ottakring. Primary endpoint: Frequency and severity of hypoglycaemic episodes. Started Aug 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
Postprandial hyperinsulinemic hypoglycemia (PHH)
Beyond the preview
Go deeper on 2020-006127-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006127-34.